← Back to Discover
SR ONE CAPITAL MANAGEMENT, LP
Period ended Jun 30, 2026 · Latest filing Aug 12, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $1,039,007,705
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Veradermics, Inc. · Common Stock · 922967104 · shares: $295,285,652
- Zenas BioPharma, Inc · Common Stock · 98937L105 · shares: $127,860,735
- CRISPR Therapeutics AG · Common Shares · H17182108 · shares: $111,194,134
- Avalyn Pharma, Inc · Common Stock · 05348Y105 · shares: $108,920,725
- Design Therapeutics, Inc. · Common Stock · 25056L103 · shares: $94,438,108
- Odyssey Therapeutics, Inc. · Common Stock · 67613T104 · shares: $71,002,261
- Alumis Inc. · Common Stock · 022307102 · shares: $55,151,473
- ORIC Pharmaceuticals, Inc. · Common Stock · 68622P109 · shares: $49,984,609
- Mineralys Therapeutics Inc. · Common Stock · 603170101 · shares: $42,195,803
- ARS Pharmaceuticals, Inc. · Common Stock · 82835W108 · shares: $32,143,353
Reported holdings
15 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Veradermics, Inc. | Common Stock | 922967104 | — | 2,401,868 shares | $295,285,652 |
| Zenas BioPharma, Inc | Common Stock | 98937L105 | — | 5,037,854 shares | $127,860,735 |
| CRISPR Therapeutics AG | Common Shares | H17182108 | — | 2,038,763 shares | $111,194,134 |
| Avalyn Pharma, Inc | Common Stock | 05348Y105 | — | 3,308,649 shares | $108,920,725 |
| Design Therapeutics, Inc. | Common Stock | 25056L103 | — | 6,526,476 shares | $94,438,108 |
| Odyssey Therapeutics, Inc. | Common Stock | 67613T104 | — | 3,794,883 shares | $71,002,261 |
| Alumis Inc. | Common Stock | 022307102 | — | 1,959,896 shares | $55,151,473 |
| ORIC Pharmaceuticals, Inc. | Common Stock | 68622P109 | — | 4,615,384 shares | $49,984,609 |
| Mineralys Therapeutics Inc. | Common Stock | 603170101 | — | 1,563,966 shares | $42,195,803 |
| ARS Pharmaceuticals, Inc. | Common Stock | 82835W108 | — | 4,012,903 shares | $32,143,353 |
| Mobia Medical, Inc | Common Stock | 60705V103 | — | 1,986,072 shares | $26,613,365 |
| Nkarta, Inc. | Common Stock | 65487U108 | — | 3,333,333 shares | $9,433,332 |
| Oculis Holding AG | Ordinary Shares | H5870P102 | — | 641,022 shares | $8,890,975 |
| Ultragenyx Pharmaceutical Inc. | Common Stock | 90400D108 | — | 137,753 shares | $4,599,573 |
| enGene Holdings Inc. | Common Shares | 29286M105 | — | 747,750 shares | $1,293,607 |